LGALS3, galectin 3, 3958

N. diseases: 557; N. variants: 15
Disease: Malignant neoplasm of stomach ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach 		0.370 Biomarker disease BEFREE Ablation of human telomerase reverse transcriptase (hTERT) induces cellular senescence in gastric cancer through a galectin-3 dependent mechanism. 27494887 2016
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach 		0.370 Biomarker disease BEFREE The cellular localization of ANXA2 and GAL3 in the GC cell lines was evaluated by immunofluorescence. 25034653 2015
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach 		0.370 Biomarker disease CTD_human Taken together, we elucidated in this study that germline variant of gal-3H(64) increases nuclear accumulation of β-catenin and promotes TCF transcriptional activity and enhances more the galectin-3's role in gastric cancer progression. 21750908 2011
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach 		0.370 AlteredExpression disease BEFREE Galectin-3 germline variant at position 191 enhances nuclear accumulation and activation of β-catenin in gastric cancer. 21750908 2011
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach 		0.370 Biomarker disease BEFREE Galectin-3 has the potential to serve as a useful pharmacological target for prevention of gastric cancer metastasis. 21966428 2011
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach 		0.370 Biomarker disease BEFREE We conclude that galectin-3 is involved in cancer progression and malignancy by modulating the expression of several relevant genes, and inhibition of galectin-3 may be an approach to improve chemotherapy of gastric cancers. 19843071 2010
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach 		0.370 Biomarker disease BEFREE Galectin-3 might be a potential therapeutic target for the prevention and treatment of gastric cancer progression. 19818782 2010
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach 		0.370 AlteredExpression disease BEFREE Reduced gal-3 expression was associated with lymph node metastasis, advanced stage and tumor differentiation in gastric cancer. 16619546 2006